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Autism Spectrum Disorder (ASD) refers to a group of heterogeneous neurodevelopmen-
tal disorders that are uniﬁed by impairments in reciprocal social communication and a
pattern of inﬂexible behaviors. Recent genetic advances have resolved some of the com-
plexity of the genetic architecture underlying ASD by identifying several genetic variants
that contribute to the disorder. Different etiological pathways associated with ASD may
converge through effects on common molecular mechanisms, such as synaptogenesis,
neuronal motility, and axonal guidance. Recently, with more sophisticated techniques, neu-
roimaging, and neuropathological studies have provided some consistency of evidence that
altered structure, activity, and connectivity within complex neural networks is present in
ASD, compared to typically developing children.The imaging-genetics approach promises to
help bridge the gap between genetic variation, resultant biological effects on the brain, and
production of complex neuropsychiatric symptoms. Here, we review recent ﬁndings from
the developing ﬁeld of imaging-genetics applied to ASD. Studies to date have indicated
that relevant risk genes are associated with alterations in circuits that mediate socio-
emotional, visuo-spatial, and language processing. Longitudinal studies ideally focused on
early development, in conjunctionwith investigation for gene–gene, and gene–environment
interactionsmaymove the promise of imaging-genetics inASDcloser to the clinical domain.
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INTRODUCTION
The Autism Spectrum Disorder (ASD) refers to a group of het-
erogeneous neurodevelopmental disorders that are uniﬁed by
impairments in reciprocal social communication, and a pattern
of inﬂexible behaviors (First, 2000). ASD affects roughly 1 in 150
people, and is four times as common in males than in females
(Fombonne, 2001). The severity of ASD impairment ranges across
the spectrum from mild to profound, with approximately 40% of
affected individuals exhibiting signiﬁcant cognitive deﬁcit (Bau-
man, 2010). This complex disorder was ﬁrst described in the early
1940s, in separate reports by Leo Kanner and Hans Asperger,
describing children with characteristic symptoms of ASD, with
or without language impairments (Kanner, 1971; Szatmari, 2000).
These seminal reports laid the foundation for diagnostic distinc-
tions between autistic and Asperger’s disorder, which the ﬁeld is
now moving away from as the search for biological markers of
the complex heterogeneity that exists across the autism spectrum
continues (Szatmari, 2011). By the late 1970s, the substantial role
that genetic factors play in conferring risk for ASD was estab-
lished (Folstein and Rutter, 1977). Over the past decade, technical
advances have led tomajor researchdiscoveries inASD,moving the
ﬁeld closer to understanding the complex etiological mechanisms
that contribute to the disorder. Genetic studies have highlighted
the substantial heterogeneity of the genetic architecture underly-
ing ASD (Geschwind, 2011). Functional analyses have indicated
that several ASD associated gene protein products interact in
pathways involved in neuronal architecture, synapse formation,
and function (State and Levitt, 2011; Marshall and Scherer, 2012).
Post-mortem work has highlighted evidence for altered brain
development in ASD that affects neuron number, axon density,
and the formation of neural circuits (Zikopoulos andBarbas, 2010;
Courchesne et al., 2011;Voineagu et al., 2011).Neuroimaging stud-
ies inASDhave provided in vivo evidence of: (i) altered cortical and
subcortical brain development (Schumann et al., 2010; Nordahl
et al., 2012), (ii) impaired integrity among white matter connec-
tions (Barnea-Goraly et al., 2010; Ameis et al., 2011; Shukla et al.,
2011), and (iii) atypical network activity and connectivity within
frontal and temporal circuits, important for socio-emotional, and
language function, in affected individuals (Just et al., 2004;Wicker
et al., 2008; Di Martino et al., 2009). Taken together, converging
lines of evidence point to an etiological role for biological path-
ways that impact on synapse structure and transmission at the
genetic level and fronto-temporal network structure and connec-
tivity at the circuit-based level. A detailed understanding of just
how genetic variation translates into alterations within speciﬁc
circuits is now needed for therapeutic advancement in ASD. The
imaging-genetics strategy has proven to be a powerful tool for
studying complex neuropsychiatric disorders (Meyer-Lindenberg
and Weinberger, 2006). Studies using this method have begun to
bridge the gap between genetic variation, neural mechanisms, and
psychiatric symptoms. In the present article, we review prelimi-
nary ﬁndings from imaging-genetics research in ASD, and discuss
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optimal avenues for leveraging this method to advance the ﬁeld
further. We begin with a brief narrative summary of relevant
genetics and brain ﬁndings in ASD.
SUMMARY OF THE GENETICS OF ASD
The ability to sequence genetic information, and performgenome-
wide scanning in large population studies has provided valuable
and novel insights into some of the etiological complexity under-
lying ASD. In approximately 10% of individuals with ASD, the
disorder can be attributed to known single-gene mutation syn-
dromes, such as fragile X syndrome and tuberous sclerosis com-
plex, and identiﬁed metabolic conditions (Schaaf and Zoghbi,
2011). Genome-wide screening for copy number variants (CNVs),
describingDNA segments (>1 kb)with varying numbers of copies
between individuals, has implicated increased rates of de novo
CNVs in ASD (i.e., ∼6% in simplex and multiplex ASD families
versus ∼1% in the general population; Pinto et al., 2010). Rele-
vant de novo genomic imbalances can nowbe detected in 7–10%of
idiopathic autism cases (Schaaf and Zoghbi, 2011). Nevertheless,
no single risk locus has been able to account for more than ∼1%
of affected individuals. Further, recent CNV analyses have esti-
mated that there are at minimum hundreds of target loci where
CNV mutations can lead to ASD (Levy et al., 2011). Although
genome-wide association studies (GWAS) have implicated a small
number of common genetic variants that confer risk for ASD [i.e.,
cadherin 9 and 10 (Wang et al., 2009), semaphorin-5A (SEMA5A;
Weiss et al., 2009), contactin-associated protein-like 2 (CNTNAP2;
Arking et al., 2008), the absence of successful replication between
studies and small effect sizes found for identiﬁed risk variants, has
diminished previous estimation of the role that common genetic
variation plays in causing autism (Geschwind, 2011). However,
given the substantial genetic heterogeneity in ASD, sample sizes
of current GWAS may still be too small to detect common vari-
ants of small effect. In recent reviews of the genetics literature,
a loading threshold for ASD has been proposed, such that some
rare de novo CNVs may have large (causal) impact on ASD sus-
ceptibility, while CNVs with smaller effects may act in concert
with other rare or common genetic or environmental factors, to
push the genetic load over the threshold for phenotypic expres-
sion (Marshall and Scherer, 2012). Diverse genetic factors may
then contribute to the overlapping ASD phenotype through con-
vergent inﬂuence on common biological pathways. Functional
analyses of ASD risk genes have highlighted the importance of
gene pathways involved in: synaptogenesis, axon guidance, and
neuronal motility (Geschwind, 2011; Gilman et al., 2011; Marshall
and Scherer, 2012). However, inconsistencies between these func-
tional analyses indicate that knowledge of common etiological
pathways contributing to ASD remains preliminary.
SUMMARY OF BRAIN FINDINGS IN ASD
As with genetics research, technical advances in non-invasive neu-
roimaging and post-mortem analysis over the last decade have
led to an improved understanding of the neural correlates of
idiopathic ASD. Post-mortem and neuroimaging studies now
point to altered brain development in ASD, involving disrupted
structure and function within fronto-temporal circuits that medi-
ate socio-communicative behavior. For example, a recent study
demonstrated a 67% increase in the number of neurons within the
prefrontal cortex in ASD brain, pointing to excess prenatal neural
proliferation, decreased prenatal or postnatal apoptosis, or both
(Courchesne et al., 2011). Another report demonstrated altered
axon density and myelin impairment in fronto-limbic white mat-
ter in post-mortem ASD (Zikopoulos and Barbas, 2010). Other
research has indicated that genes that help to distinguish frontal
and temporal cortex in typical brain development are diminished
in ASD brain (Voineagu et al., 2011). Preliminary ﬁndings have
also indicated that gene expression changes in ASD brain may
involve gene systems that regulate neuronal synapses (Voineagu
et al., 2011). The initial results from longitudinal magnetic reso-
nance imaging (MRI) research have provided in vivo evidence that
abnormal brain development in ASD involves increased frontal
and temporal gray and white matter volume, and enlarged amyg-
dala volume in ASD children between 2 and 5 years of age, com-
pared to controls (Schumann et al., 2010; Nordahl et al., 2012).
While generalized brain overgrowth may likely characterize early
childhood ASD, MRI studies have found evidence of more local-
ized volumetric abnormalities within frontal white matter, and
frontal and temporal gray matter regions in older children, ado-
lescents and adults with ASD (Herbert et al., 2003; Hyde et al.,
2010). A recent longitudinal diffusion tensor imaging (DTI) study
that reported on the developmental trajectory of white matter
microstructure in infant siblings of children with ASD (at high-
risk for the disorder) has provided in vivo evidence of an evolving
pattern of brain disruption in early childhood ASD. In this study,
infant siblings diagnosed with ASD at 24months of age exhib-
ited increased fractional anisotropy (an index of microstructural
white matter integrity) across several interhemispheric and asso-
ciation white matter pathways at 6 months of age, and altered
white matter development between 6 and 24months of age, when
compared to matched high-risk siblings without an ASD diag-
nosis at 24 months (Wolff et al., 2012). In conjunction with
DTI studies of older children, and adults with ASD, these ﬁnd-
ings contribute to strong evidence for a disruption in the normal
development of whitematter tractmicrostructuremediating long-
range brain connectivity (Pugliese et al., 2009; Kumar et al., 2010;
Ameis et al., 2011; Radua et al., 2011). Functional neuroimaging
[i.e., functional MRI (fMRI) and positron emission tomography
(PET)] results in ASD have varied depending on methods and
task paradigms used (Schultz et al., 2000; Pierce et al., 2001, 2004;
Hadjikhani et al., 2004). However, a recent meta-analysis of fMRI
and PET studies examining children, adolescents and adults with
ASD, compared to controls, provides helpful insights into over-
all trends across this literature. This meta-analysis demonstrated
that individuals with ASD exhibit: (i) reduced probability for acti-
vation of higher-order social (i.e., amygdala, cingulate, fusiform
gyrus, insula) and executive processing (i.e.,dorsolateral prefrontal
cortex) structures and (ii) increased activation of lower-order
structures that mediate primary motor and sensory processing
during complex socio-emotional and executive task performance
(Di Martino et al., 2009). Other functional imaging work mea-
suring correlated activity between regions, as a surrogate index of
network connectivity, has consistently implicated reduced func-
tional connectivity in ASD across neural networks that mediate
complex tasks (Just et al., 2004, 2007; Kana et al., 2006; Kennedy
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and Courchesne, 2008; Wicker et al., 2008). Further, preliminary
work using transcranial magnetic stimulation, a method enabling
stimulation of the cortex using magnetic pulses, has implicated
impaired cortical inhibition in young adults with ASD, consis-
tent with reduced γ-aminobutyric acid (GABA) receptor protein
expression found in post-mortem autistic brain tissue (Fatemi
et al., 2009). Impaired cortical inhibition may be one factor that
contributes to altered (and variable) brain activation inASD (Enti-
cott et al., 2010). Thus, while post-mortem data has pointed to an
early event that disrupts development of neurons and their con-
nections, neuroimaging ﬁndings have provided in vivo evidence
for abnormal frontal and temporal brain growth, altered white
matter tract development, abnormal activation, and reduced inte-
gration of complex neural circuits. Although brain alterations in
ASD are widespread, ﬁndings that implicate abnormal frontal and
temporal circuitry recurs throughout the literature. Early valida-
tion of theories positing that brain-based phenotypes inASD likely
evolve across development (Belmonte et al., 2004), based on the
results of the ﬁrst developmental studies published in ASD (Wolff
et al., 2012), has emphasized the critical need for longitudinal
research in a disorder where abnormal development is essential to
the diagnosis.
IMAGING-GENETICS REVIEW IN ASD
In the following sections, we present our review of imaging-
genetics research in ASD. A sensitive search strategy in three
relevant article databases (MEDLINE, Embase, and PsycINFO)
using the OvidSP database interface was completed to ﬁnd Eng-
lish language references on the topic of neuroimaging research of
genes associated with ASD. Our search terms included the data-
base subject headings for the concepts of pervasive developmental
disorders, genetics, and magnetic resonance imaging. The OvidSP
interface multipurpose search command (.mp.) was used to search
for additional search terms derived from the “used for” section of
the database subject headings; unlimited truncation symbol “∗”
was applied to capture variation in sufﬁx endings when appro-
priate. Relevant articles retrieved from our search included: (i)
11 imaging-genetic studies that have examined the brain effects
of common genetic variants associated with idiopathic ASD, and
(ii) 34 neuroimaging studies focused on investigating the neural
alterations associated with syndromic autism. Here, we provide a
comprehensive review of those studies that have examined genes
associatedwith idiopathicASDbasedonGWAS,and genome-wide
CNV studies (see Table 1); we include brief discussion of studies
that have examined common variants in genes that code for sig-
naling proteins in ASD as work in this area could have important
therapeutic implications. Although a full review of neuroimag-
ing studies that have focused on genetic syndromes associated
with autism is beyond the scope of this article, we present a num-
ber of select examples from this literature. These include studies
describing brain structure in genetic syndromes that have high
rates of ASD (i.e., fragile X syndrome, 22q.11.2 deletion syndrome,
tuberous sclerosis complex) highlighting the value of utilizing the
neuroimaging approach to search for common intermediate phe-
notypes. Here, we chose to include studies comparing syndromic
and idiopathic autism groups to a relevant control group; if no
such study design was available in the current literature, articles
comparing a genetic syndrome group, with or without co-morbid
autism, were included.
The majority of imaging-genetics studies relevant to ASD are
designed in accordance with the intermediate phenotype concept
applied to neuropsychiatry. The intermediate phenotype concept
assumes that genes do not code for psychopathology but medi-
ate risk for symptom expression through their effects on relevant
neural systems. Individuals carrying risk alleles for a given disor-
der would therefore exhibit effects in the brain, even in the absence
of clinical symptoms (Meyer-Lindenberg and Weinberger, 2006).
Based on this premise, intermediate “brain-based” phenotypes
associated with common genetic variants can be studied in healthy
populations, an advantageous design for collecting large samples
and minimizing confounds associated with illness. Research that
has utilized the intermediate phenotype approach to characterize
the neural effects of ASD-implicated genes can be broadly orga-
nized into studies of: (i) common variants within genes important
for cell–cell interactions, and (ii) variation in genes encoding
signaling proteins (i.e., neuropeptides, neurotransmitters, and
neurotrophins).
GENES AFFECTING CELL–CELL INTERACTION
A small number of imaging-genetics studies have begun to char-
acterize the neural effects of neurexin superfamily gene variants,
implicated in ASD. The neurexins (Nrxn) are largely presynap-
tic proteins that form a trans-synaptic complex with postsynaptic
neuroligins (Nlgn). Deletions affecting the Nrxn1-a gene (1.1Mb
region, chromosome 2p16.3) have been repeatedly observed in
ASD (Sebat et al., 2007; Szatmari et al., 2007; Kim et al., 2008;
Marshall et al., 2008; Yan et al., 2008) and schizophrenia (Walsh
et al., 2008; Kirov et al., 2009; Rujescu et al., 2009). Mutations
have also been found in Nlgn3 (Xq13.1) and Nlgn4X (Xp22.32-
p22.31) in ASD (Jamain et al., 2003; Laumonnier et al., 2004;
Yan et al., 2005). Other CNVs found to affect the Shank family
of scaffolding proteins (Shank 1–3) in ASD (Pinto et al., 2010),
which bind to the Nlgns, provide further evidence that disrup-
tion to the Nrxn/Nlgn/Shank synaptic complex confers risk for the
disorder. Animal models point to the presence of alterations in
excitatory synaptic neurotransmission, and excitatory/inhibitory
balance in a-Nrxn knock out (KO) mice, as well as mice featuring
Nlgn and Shank3 protein disruption (Sudhof, 2008; Etherton et al.,
2009; Bangash et al., 2011). In these mouse models, phenotypic
traits analogous to autism (i.e., repetitive grooming, and impaired
social interactions) have also been found. Further, a microdeletion
syndrome affecting chromosome 22q13.3 resulting in haploin-
sufﬁciency of Shank3 leads to a developmental phenotype that
includes autistic symptoms (Philippe et al., 2008). A phenotypic
characterization study of eight children (5–8 years, three girls)
with 22q13.3 microdeletion affecting Shank3, described slowed
motor and language development, repetitive behaviors, ADHD
symptoms,mild to severe delay in cognitive milestones and signif-
icant social and communication impairments in affected children.
Neuroimaging abnormalities found in 22q13.3microdeletion syn-
drome included: MRI-measured thinning of the corpus callosum,
and temporal hypoperfusion,measured using PET (Philippe et al.,
2008). Of the Nrxn/Nlgn/Shank complex genes, the neural effects
associated with common variation in the Nrxn1 gene has been
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Table 1 | Imaging-genetics studies using the intermediate phenotype approach to examine the neural effects of ASD-related risk genes.
Study Participants (F:M):
mean±SD
Gene Imaging method Gene variant studied:
genotype group (n)
Key results
NEUREXIN SUPERFAMILY GENES
Voineskos et al.
(2011)
53HCs
(15F:38M):
39±13.1
Neurexin 1 MRI: cortical/subcortical
volume
rs1045881: C/C (33);
C/T,T/T (20)
↓Frontal WM volume associated with
rs1045881C,rs858932G
rs858932: GG (6); G/C
(33); C/C (14)
↓Finger-tapping speed in rs1045881C
Tan et al. (2010) 314HCs CNTNAP2 MRI (VBM): GM/WM
volume
rs779475: T/T; T/A, A/A rs779475T/T: ↓ volume in cerebellum,
fusiform gyrus, posterior occipital,
frontal pole, cingulum, thalamic
radiations, IFOF
DTI: voxel-wise FA
analysis
Sex-speciﬁc associations with
rs779475T/T: ↓FA in right IFOF in
males, ↓FA in right thalamic radiation in
females
Scott-Van Zeeland
et al. (2010)
Sample I –
16ASD; 16TD:
12±2
CNTNAP2 fMRI:
reward-processing task
rs2710102: Sample I (fMRI)-rs2710102C: ↑mPFC
activity on reward-processing, reduced
left-lateralized mPFC network
Sample II – 39HC
children:
(16F:23M)
fcMRI Sample I: C/C,T/C (9);
T/T(23)
Sample II (fcMRI)- rs2710102C:
↓long-range (mPFC to
occipital/temporal cortex) ↑short-range
(mPFC to frontal cortex) connectivity
Sample II: C/C,T/C (29);
T/T (10)
Whalley et al.
(2011)
66HCs
(35F:31M):∼20±2
CNTNAP2 fMRI: verbal ﬂuency
task
rs2710102:C/C(n=16);
C/T, T/T (n=50)
On verbal ﬂuency:
rs779745:T/T(n=8);
T/A, A/A (n=57)
↑Right IFG activity in rs2710102C/C
↑Right MTG activity in rs779475T/T
OXYTOCINANDARGININEVASOPRESSIN RECEPTOR GENES
Tost et al. (2010) MRI: 212HCs:
29.9±9
OXTR sMRI (VBM) sMRI: rs53576: G/G
(95); G/A (96); A/A (21)
↓Hypothalamus volume in rs53576A
fMRI: 228HCs:
31.9±9.9
fMRI: face processing
task (TPQ)
fMRI: rs53576: G/G
(102); G/A (100);
A/A (26)
↑Amygdala volume in rs53576A males
↓Reward dependence onTPQ in
rs53576A (correlated with
hypothalamus/amygdala volume)
Face processing: ↓amygdala activity
↑amygdala–hypothalamus coupling in
rs53576A
Inoue et al. (2010) 208 HCs
(143M:65F):
33.9±11.6
OXTR MRI: ROI volume:
amygdala, hippocampus
rs2254298: A/A(77);
A/G(85); G/G(44)
↑Amygdala volume in rs2254298A
Furman et al.
(2011)
51 female HCs:
13±1.5
OXTR MRI (VBM): GM/WM
volume+ROI volume:
amygdala
rs2254298: A/G (16);
G/G (35)
↑GM volume in rs2254298G/G
↓Amygdala volume in rs2254298G/G
Meyer-
Lindenberg et al.
(2011)
258 HCs
(149F:109M):
31.5±9.6
AVPR1A fMRI: face processing
task
(Select RS1, RS3
ASD-risk alleles): RS3
334bp (57); RS1 312bp
(39); RS1 320bp (54)
↑Left amygdala activity in RS3 334bp
↑Left amygdala activity in RS1 312bp
versus 320bp
↓Left amygdala activity in RS1 320bp
SD, standard deviation; HCs, healthy controls; F, females; M, males; CNTNAP2: contactin-associated-protein like 2; OXTR, oxytocin receptor gene; AVPR1A, arginine
vasopressor receptor 1A gene; MRI, magnetic resonance imaging; sMRI, structural MRI;VBM, voxel-based morphometry; DTI, diffusion tensor imaging; FA, fractional
anisotropy; fMRI, functional MRI; fcMRI, functional connectivity MRI; GM, grey matter;WM, white matter;TPQ, tridimensional personality questionnaire; ROI, region
of interest; IFOF, inferior-fronto-occipital fasciculus; mPFC, medial prefrontal cortex; IFG, inferior frontal gyrus; MTG, medial temporal gyrus.
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studied in a healthy sample. Voineskos and colleagues exam-
ined structural brain differences associated with Nrxn1 variants
(rs1045881C and rs858932G) in a sample of 53 healthy controls.
Compared to non-risk homozygotes,healthy individualswhowere
homozygous for the rs1045881C risk allele exhibited reduced
frontal lobe white matter volume, thalamic volume (Voineskos
et al., 2011), and slower ﬁnger-tapping speed that correlated
positively with reduced frontal white matter volume. An in sil-
ico analysis of the rs1045881C single nucleotide polymorphism
(SNP) indicated that this 3′ untranslated region variant creates a
microRNA binding site. These in silico results suggest that com-
mon rs1045881 variation could exert structural effects on frontal
lobe white matter through altered Nrxn1 expression.
The CNTNAP2 gene (2.3Mb region, chromosome 7q35-36)
is another member of the neurexin superfamily, associated with
autism (Alarcon et al., 2008; Arking et al., 2008; Bakkaloglu et al.,
2008), and speciﬁc language impairment (Vernes et al., 2008).
Roughly 70%of OldOrderAmish childrenwith cortical dysplasia-
focal epilepsy syndrome, secondary to a recessive nonsense CNT-
NAP2 mutation, exhibit ASD (Strauss et al., 2006). The CNT-
NAP2 gene encodes a neural transmembrane protein, involved
in neuronal–glial interactions, and in clustering K+ channels in
myelinated axons (Strauss et al., 2006; Penagarikano et al., 2011).
A recent study demonstrated that CNTNAP2 KO mice exhibit
an ASD-like phenotype that includes: seizures, hyperactivity, sen-
sory alterations, perseveration, and reduced ultrasonic vocaliza-
tions and social interactions, when compared to wild-type mice
(Penagarikano et al., 2011). Further, CNTNAP2 KO mouse brain
ﬁndings have implicated the importance of CNTNAP2 for normal
neural migration, GABAergic inhibitory interneuron regulation,
and synchronous neuronal ﬁring (Penagarikano et al., 2011). In
humans, CNTNAP2 expression is enriched in frontal, temporal,
striatal, and thalamic regions (Alarcon et al., 2008). To date, three
imaging-genetics studies have examined the neural effects associ-
ated with common variants in CNTNAP2. In the largest of these
studies, Tan and colleagues used structural MRI and DTI to exam-
ine brain effects associated with the CNTNAP2 rs779475 SNP
in 314 healthy individuals. In this study, risk allele homozygotes
(rs779475 T/T) exhibited reduced gray matter volume in cerebel-
lum, frontal, and occipital lobes, and reduced white matter volume
in posterior thalamic radiations, right rostral cingulum bundle,
and caudal portions of the right inferior-fronto-occipital fascicu-
lus, compared to a combined group of rs779475T heterozygotes
and non-risk homozygotes (A/A; Tan et al., 2010). More dramatic
reductions in right frontal gray matter volume were found in male
risk homozygotes and reduced fractional anisotropy on DTI (a
sign of impaired white matter integrity) was exhibited in the
right inferior fronto-occipital fasciculus by male risk homozygotes
only. These ﬁndings pointed to a sex-speciﬁc gene effect within a
right fronto-temporo-occipital circuit that has been implicated in
ASD. A subsequent study found increased fMRI measured activa-
tion in the right inferior frontal and right medial temporal gyrus
during language performance in healthy risk homozygotes at the
rs2710102 and rs779475 SNPs, respectively (Whalley et al., 2011).
Finally, Scott-Van Zeeland and others reported on associations
between common CNTNAP2 variation and fMRI activation in
two samples (Scott-Van Zeeland et al., 2010). These researchers
ﬁrst genotyped 16 children with ASD and 16 typically developing
controls at the rs2710102 SNP and found increased medial pre-
frontal cortex activation during a reward-processing task in risk
carriers, regardless of diagnosis. Functional connectivity analysis,
measuring correlated activity with medial prefrontal cortex, indi-
cated that while non-risk homozygotes exhibited a left-lateralized
pattern of medial prefrontal cortex connectivity, risk carriers acti-
vated a diffuse, bilateral set of frontal and temporal regions. In
a separate cohort of 39 typically developing children, the risk
allele was further associated with reduced long-range connectiv-
ity between frontal, temporal and occipital regions, and increased
local connectivity between left and right frontal cortex (Scott-Van
Zeeland et al., 2010).
As would be anticipated, the aforementioned imaging-genetics
research examining neural effects of neurexin superfamily genes
has indicated that genetic variation in genes linked to ASD likely
confer illness risk through their inﬂuence on structure and func-
tion within cortical networks involved in socio-communicative
behaviors. Further, genes associated with ASD, have been associ-
ated with other neuropsychiatric disorders, as well as intellectual
disability. It is now well established that the same genetic lesion
can lead to different behavioral and cognitive phenotypes, even
within the same family (Blackwood et al., 2001). One advan-
tage of imaging-genetics is that the effects of a risk gene can be
mapped more consistently onto neural circuitry that may confer
vulnerability across different disorders. In the case of Nrxn1 varia-
tion, altered frontal white matter volume, and secondary effects on
frontal connectivity, may contribute to vulnerability for ASD and
schizophrenia (Voineskos et al., 2011); disorders that share promi-
nent abnormalities with respect to frontal lobe structure, activity,
and frontal lobe mediated behaviors (Ameis et al., 2011; Radua
et al., 2011; Voineskos et al., 2011). Similarly, CNTNAP2 variation
may contribute to vulnerability for ASD and speciﬁc language
impairment through inﬂuence on gray and white matter struc-
ture, activation and connectivity within a broad fronto-temporo-
occipital network involved in visuo-spatial and language functions
(Catani and Thiebaut de Schotten, 2008; Philippi et al., 2009).
As common genetic variations are found in healthy populations,
they are clearly not sufﬁcient to cause psychiatric disturbance,
however, their effects may be accentuated by other genetic and
environmental risk factors that together augment risk forASD.The
disrupted-in-schizophrenia (DISC1) gene (chromosome 1q42) is
an example of a susceptibility locus for major mental illness that
could potentially act as an additive genetic risk factor in ASD.
The potential role for DISC1 in risk for mental illness was ﬁrst
identiﬁed based on a balanced chromosomal t(1;11) transloca-
tion that disrupted the DISC1 protein sequence, and segregated
in a highly signiﬁcant manner with schizophrenia, bipolar disor-
der, and major depression, in a large and unique Scottish family
(Millar et al., 2000; Blackwood et al., 2001). Subsequently, genome-
wide screening found CNVs affecting DISC1 in a boy with ASD
(Williams et al., 2009), and two brothers with ASD and mental
retardation (Crepel et al., 2010). DISC1 variants have also been
implicated in ASD by family-based association studies of Finnish
and Chinese Han families ascertained for ASD (Kilpinen et al.,
2008; Zheng et al., 2011). The DISC1 gene encodes an intracel-
lular scaffolding protein that interacts with proteins involved in
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regulation of early brain development, including neural prolifer-
ation and migration, synapse formation and maintenance (Mao
et al., 2009; Ayhan et al., 2011; Brandon and Sawa, 2011). A recent
study of DISC1 function in an animal model identiﬁed two dis-
crete pathways whereby DISC1 interactions with different proteins
contributed to distinct neurodevelopmental processes, including
dendritic development, and neuronal positioning (Kang et al.,
2011). Imaging-genetics studies have indicated thatDISC1 variants
inﬂuence cortical/hippocampal structure (Callicott et al., 2005;
Di Giorgio et al., 2008; Szeszko et al., 2008; Brandon and Sawa,
2011; Brauns et al., 2011), and white matter integrity (Sprooten
et al., 2011) in healthy adults. Of particular relevance to our
discussion of ASD, is a longitudinal imaging-genetics study of
255 typically developing children and adolescents that found an
association between common DISC1 variation (in rs6675281 and
rs821616) and age-related rates of cortical thickness change within
frontal and temporal cortex (Raznahan et al., 2011). Interestingly, a
recent study indicated that DISC1 variation might increase risk for
psychiatric illness through epistatic interactions with other genes
within the DISC1 interactome (Kang et al., 2011). The DISC1
example may then provide a helpful model for how the same gene
can confer risk for multiple psychiatric disorders based on the tim-
ing and location of additive risk effects and their discrete impact
on the developing brain.
GENES THAT AFFECT NEURAL SIGNALING AND THEIR THERAPEUTIC
IMPLICATIONS
Gene variants inﬂuencing neuropeptide regulation
A number of genes involved in neural signaling may have impli-
cations for ASD pathogenesis and available therapeutics. The
oxytocin receptor (OXTR, chromosome 3p25) gene is one such
example. The OXTR gene encodes the receptor protein for oxy-
tocin. Oxytocin is a neuropeptide with signiﬁcant importance for
regulation of social cognition and behavior (Meyer-Lindenberg
et al., 2011). High levels of plasma oxytocin have been associated
with prosocial behavior. In contrast, low peripheral oxytocin lev-
els have been found in individuals with ASD (Green et al., 2001;
Meyer-Lindenberg et al., 2011). The OXTR gene has been impli-
cated in ASD based on a number of positive association studies
with common variants in OXTR and a rare deletion for OXTR
that was found in an autistic proband and his mother (Wu et al.,
2005; Lauritsen et al., 2006; Jacob et al., 2007; Gregory et al., 2009).
The brain structural/functional, and behavioral effects associated
with the ASD-implicated OXTR rs53576A SNP have recently been
examined in a large sample of healthy adults (n = 212). In this
study, an allele-load dependent association was found for reduced
hypothalamus volume in healthy rs53576A risk allele carriers. An
allele-load dependent effect was also found for increased right
amygdala volume in male risk carriers only. Additionally, risk
homozygotes exhibited decreased amygdala activity and increased
amygdala–hypothalamus coupling during face processing. Risk
homozygotes also had the lowest scores on reward dependence
for the tridimensional personality questionnaire (TPQ), a mea-
sure of prosocial temperament. Finally, lower reward dependence
scores were associated with increased amygdala and decreased
hypothalamus volumes (Tost et al., 2010). Studies of another com-
mon OXTR variant (rs2254298), associated with ASD, have also
demonstrated associations between OXTR risk alleles and altered
amygdala volume (Inoue et al., 2010; Furman et al., 2011). Argi-
nine vasopressin is an oxytocin related neuropeptide with similar
importance for social regulation (Meyer-Lindenberg et al., 2011).
Two of three polymorphic microsatellite repeats in the 5′ ﬂank-
ing region of the arginine vasopressin receptor 1A gene (AVPR1A;
chromosome 12q) have alleles featuring overtransmission (334-
and 340-bp RS3 alleles) and under transmission (312-bp allele of
RS1) in ASD (Wassink et al., 2004; Meyer-Lindenberg et al., 2011).
Interestingly, common variation at AVPR1A has been associated
with differential activity of the amygdala during face processing
(Meyer-Lindenberg et al., 2009). Although the speciﬁc effects of
OXTR and AVPR1A variation on oxytocin and arginine vaso-
pressin levels in the brain remain unclear, current data suggests
that variation at these sites plays an important role in shaping
social circuitry that has been linked to ASD impairments.
Therapeutic implications related to oxytocin system research
Neuroscience research examining the effects of oxytocin in the
brain has fueled excitement about the potential use of oxytocin
as a therapeutic agent in ASD. Neuroimaging studies have indi-
cated that oxytocin administration promotes prosocial effects in
healthy controls that seem to be mediated through altered limbic
circuit activation in response to social stimuli (Gamer et al., 2010;
Meyer-Lindenberg et al., 2011). Preliminary evidence from small
randomized control trials has indicated that oxytocin treatment
by intranasal administration or infusion may improve repetitive
behaviors and social cognition in ASD (Hollander et al., 2003,
2007; Guastella et al., 2010). A number of clinical trials are cur-
rently underway to further examine the therapeutic utility and
safety of oxytocin as a treatment in ASD (http://clinicaltrials.gov).
Translational successes with oxytocin have also fueled prelimi-
nary candidate gene research that has found a positive association
between CD38, a transmembrane protein involved in oxytocin
secretion, in ASD (Munesue et al., 2010). Therefore, neuroscience
research has been a critical element for the validation of oxytocin
as a novel agent with considerable therapeutic potential in ASD.
Gene variants inﬂuencing neurotransmitters and neurotrophic
factors
A small number of additional preliminary studies that have exam-
ined genes that code for signaling proteins, implicated in ASD,
warrant brief discussion in this section. Monoamine neurotrans-
mitters (serotonin, dopamine, and norepinephrine) have been
implicated in a number of psychiatric disorders, including ASD
(Lam et al., 2006). In particular, platelet hyperserotonemia (Lam
et al., 2006), serotonin receptor abnormalities (Hollander et al.,
2000; Hranilovic et al., 2007), and abnormal brain serotonin
synthesis (Murphy et al., 2006) in ASD point to altered sero-
tonin regulation. Monoamine oxidase A (MAOA) metabolizes
monoamines. A VNTR polymorphism in the promoter region
of the X-chromosome linked MAOA gene results in a highly
active (MAOA-H) and less active (MAOA-L) allele (Chugani et al.,
1997). Imaging-genetics studies have associated healthy MAOA-L
allele carriers with altered structure and function within limbic
structures (Scharinger et al., 2011). Candidate gene examination
has indicated that the MAOA-L VNTR polymorphism may be
Frontiers in Psychiatry | Neuropsychiatric Imaging and Stimulation May 2012 | Volume 3 | Article 46 | 6
Ameis and Szatmari Imaging-Genetics in Autism Spectrum Disorder
preferentially transmitted in ASD (Yoo et al., 2009). The MAOA-L
allele has been associated with increased symptom severity in ASD
(Cohen et al., 2003). Recently, Davis et al. (2008) found an associ-
ation between the MAOA-L VNTR polymorphism and increased
cortical brain volume in male children with ASD. The serotonin
transporter regulates brain serotonin levels, a neurotransmitter
that plays an important role in brain growth (Raznahan et al.,
2009a). A common polymorphism involving a variable number
of tandem repeats in the 5′ promoter region (5HTTLPR) of the
serotonin transporter gene (SLC6A4) results in a short or long
allele. The 5HTTLPR short allele is associated with reduced gene
transcription (Yirmiya et al., 2002; Cohen et al., 2003), and altered
structure and activity within social circuitry in healthy controls
(Heils et al., 1996). A recent meta-analysis of candidate gene
studies that examined 5HTTLPR in ASD failed to ﬁnd an over-
all association (Huang and Santangelo, 2008). However, Wassink
et al. (2007) recently found an association between the 5HTTLPR
short allele and increased cortical gray matter volume in young
boys with ASD (aged 2–4 years). Another report found no asso-
ciation between brain structure and the 5HTTLPR short allele
in older individuals with ASD. The brain-derived neurotrophic
factor (BDNF) is involved in neurogenesis, cortical lamination,
and synaptic plasticity (Binder and Scharfman, 2004). Intracel-
lular packaging and secretion of BDNF is altered by a common
functional non-synonymous SNP within the 5′ region of the gene
(BDNFval66met). Links between this SNP and ASD are limited
to small association and candidate gene studies with mixed results
(Philippe et al., 2002; Nishimura et al., 2007; Cheng et al., 2009).
Evidence of altered peripheral BDNF levels in ASD, and increased
forebrain BDNF levels in autistic versus control brain, on post-
mortem examination, have been found (Perry et al., 2001). A
recent imaging-genetics study of the neural effects associated with
the BDNFval66met polymorphism in 41 participants with ASD
and 30 controls (∼12–64 years) found a group by genotype inter-
action in their sample. Healthy BDNF met allele carriers exhibited
decreased cortical volume and surface area in cingulate and frontal
regions compared to BDNF val homozygotes, while met allele
carriers with ASD exhibited greater volume in these regions com-
pared to their BDNF val homozygote counterparts (Raznahan
et al., 2009b). While evidence for the role of genetic variation
in MAOA, SLC6A4, and BDNF remains equivocal in ASD, prelim-
inary imaging-genetics ﬁndings suggest that common variation
in these genes could have a role in determining brain structure
in ASD. Based on these ﬁndings, continued consideration of the
potential additive risk effects conferred by genetic factors affect-
ing these neurotransmitter and neurotrophin systems is warranted
in ASD.
EXAMINING BRAIN EFFECTS IN GENETIC DISORDERS RELEVANT TO
SYNDROMIC AUTISM
Imaging studies of genetic syndromes with high rates of ASD, pro-
vide added information regarding the way risk genes confer neural
risk for illness symptoms. Fragile X syndrome is themost common
inherited form of mental retardation, affecting 1 in 4000 males
and 1 in 8000 females (Gaspar et al., 2003). Features of the fragile
X syndrome include: a long narrow face, macroorchidism, large
protruding ears, mild to moderate mental retardation, language
acquisition delay, hyperactivity, anxiety, seizures, and autistic-
like behaviors (i.e., repetitive behavior, decreased attention, and
poor eye contact; Hatton et al., 2006). Up to 30% of males
with fragile X syndrome have co-morbid autism (Fatemi and
Folsom, 2011). The fragile X syndrome is caused by a trinu-
cleotide expansion (>200 CGG repeats) in the X-linked fragile
X mental retardation 1 (FMR1) gene, resulting in hypermethy-
lation and gene silencing (Hatton et al., 2006). Gene silencing
interferes with fragile X mental retardation protein (FMRP) pro-
duction. FMRP is otherwise synthesized at synapses in response
to synaptic activation (Fatemi and Folsom, 2011). In FMR1 KO
mouse brain, and post-mortem human studies of fragile X syn-
drome, increased density of long, thin, and immature dendritic
spines found in cortex, cerebellum, and hippocampus, has indi-
cated that FMRP plays an important role in regulating normal
synaptic development/maturation (Weiler et al., 1997). Two neu-
roimaging studies that have reported on a large sample, including
male children with: idiopathic ASD (n = 63), fragile X syndrome
(n = 52), developmental delay (n = 19), and typically developing
controls (n = 31; Irwin et al., 2000), provide insights into whether
fragile X syndrome and idiopathic ASD share brain-based pheno-
types. First, Hazlett and colleagues found caudate and amygdala
volumes differentiated between IQ matched children with frag-
ile X syndrome and idiopathic ASD. Caudate enlargement was
found in fragile X syndrome children with and without autism,
but only idiopathic ASD children exhibited amygdala enlarge-
ment (Hazlett et al., 2009). A more recent report on this sample,
indicated that fragile X syndrome and idiopathic ASD children
could be further differentiated based on opposing volumetric
abnormalities in frontal and temporal cortex (i.e., increased vol-
ume in ASD, and decreased volume in fragile X syndrome with
or without co-morbid ASD). Interestingly, multivariate analysis
indicated that brain structure in children with idiopathic ASD
was more similar to typically developing children and children
with developmental delay than to children with fragile X syn-
drome, either with or without co-morbid autism (Hoeft et al.,
2011). Other ﬁndings extend previous results to adults, indi-
cating that increased volume within frontal, parietal, cingulate,
caudate, and cerebellar regions differentiates between fragile X
syndrome and ASD, while a pattern involving increased frontal
and temporal volume is more characteristic of ASD (Wilson
et al., 2009). The aforementioned neuroimaging studies examin-
ing fragile X syndrome and idiopathic ASD seem to indicate that
brain-based phenotypes in these disorders differ more than they
overlap.
The 22q11.2 microdeletion syndrome is the most common
human deletion syndrome (Goodship et al., 1998). The syndrome
is characterized by congenital heart malformations, palatal abnor-
malities, facial dysmorphology, learning difﬁculties, and devel-
opmental delay (Shprintzen, 2000a,b). Risk for psychiatric co-
morbidity is high, especially for schizophrenia in young adults
(Chow et al., 1994). The prevalence of ASD in 22q11.2 deletion
syndrome ranges from 20 to 50% (Vorstman et al., 2006; Antshel
et al., 2007; Niklasson et al., 2009). The 22q11.2 deletion syn-
drome affects approximately 45 genes (Philip and Bassett, 2011).
Neuroimaging studies in 22q11.2 deletion syndrome have impli-
cated: reduced cerebellar volume (van Amelsvoort et al., 2004),
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increased amygdala volume (Kates et al., 2006), decreased fusiform
gyrus activity during face processing, and alteredpatterns of neural
response to emotionally expressive faces (Andersson et al., 2008);
ﬁndings that overlap with neuroimaging results in ASD. A pre-
liminary study has found that children with the 22q11.2 deletion
syndrome with co-morbid autism have more pronounced amyg-
dala enlargement than affected children without autism (Antshel
et al., 2007).
Tuberous sclerosis complex is a genetic neurocutaneous syn-
drome, caused by mutations inTSC1 or TSC2 genes. Protein
products associated with TSC1 and TSC2 are critical for regu-
lating cell proliferation and differentiation. The tuberous sclerosis
complex is a multi-system disorder characterized by the devel-
opment of benign tumors that can occur in any organ system,
including the brain, where tubers are found in cortical and sub-
cortical brain regions (Tomasoni and Mondino, 2011). High rates
of mental retardation, epilepsy and ASD are found in individu-
als with tuberous sclerosis complex (Asato and Hardan, 2004).
Although some neuroimaging studies have found an association
between the presence of tubers within the temporal lobe and
autistic symptoms in tuberous sclerosis complex (Bolton and
Grifﬁths, 1997; Seri et al., 1999; Bolton et al., 2002), this asso-
ciation is not consistently found (Doherty et al., 2005; Wong
and Khong, 2006). A recent DTI study examined the microstruc-
tural integrity of the corpus callosum white matter in 40 patients
with tuberous sclerosis complex and 29 matched controls. In
this study, tuberous sclerosis complex patients exhibited signs of
altered white matter microstructure, compared to controls, how-
ever,pronounced reductions inwhitematter integritywere speciﬁc
to tuberous sclerosis complex patients with ASD (Peters et al.,
2012).
Thus far, a limited number of studies that have compared
children with syndromic autism to idiopathic autism seem to
implicate neural differences between these disorders, rather than
similarities. However, disruption affecting the amygdala and tem-
poral lobe may be one important site of overlap, where lesions
confer risk for ASD symptoms. Future studies examining indi-
viduals with a genetic lesion without autism versus those with
autism, in conjunction with comparison of an idiopathic ASD,
and relevant control group will be best suited to furthering our
understanding of how a highly penetrant genetic lesion may con-
tribute to increased risk for ASD. Reﬁned genetic mapping to
stratify participants with identiﬁed genetic syndromes according
to speciﬁc gene involvement, could narrow genetic heterogene-
ity further, and be of added beneﬁt to this line of neuroimaging
research.
CONCLUSIONS
Imaging-genetics studies applied to ASD have begun to charac-
terize pathways whereby common genetic variation in typically
developing individuals confers risk for symptoms through inﬂu-
ence on structure, activity, and connectivity within relevant neural
circuits. Neurexin superfamily genes may increase symptom risk
through altered frontal white matter structure and connectiv-
ity (Antshel et al., 2007), and disruption of fronto-temporo-
occipital circuits involved in visuo-spatial and language process-
ing (Voineskos et al., 2011). Oxytocin and arginine vasopressin
receptor genes may inﬂuence neuropeptide signaling and socio-
emotional functioning through altered structure and function
within amygdala-hypothalamic circuitry (Tan et al., 2010). While
these ﬁndings are promising, the imaging-genetics ﬁeld in ASD
is still very much in its infancy. Through further characterization
of the effects of common ASD-implicated variants on the brain,
the repository of known genetic pathways that inﬂuence risk for
ASD can be expanded. Future research efforts aimed at capitaliz-
ing on the extraordinary promise of imaging-genetics research
in ASD will beneﬁt from some key methodological advances.
First, integration of a multimodal approach to neuroimaging, in
addition to more detailed behavioral characterization for rele-
vant brain–behavior correlations, will enhance efforts to eluci-
date the relationships between genes, altered neural circuits and
behavior. Sophisticated methods used to examine gene–gene and
gene–environment interactions will be needed to characterize
the complex genetic factors contributing to ASD, such studies
will require larger sample sizes relative to those examined to
date. Further, in a common disorder inﬂuenced by rare genetic
mutations, reverse phenotyping (Schulze and McMahon, 2004;
Philippe et al., 2008), where brain-based phenotypes are char-
acterized in groups with overlapping rare genetic abnormalities,
revealed through deep gene sequencing, may be another promis-
ing approach for mapping the effects of ASD risk genes. Further,
a developmental approach where the time-dependent effects of
genetic variants inﬂuencing altered neurodevelopment are studied
longitudinally, particularly in the ﬁrst years of life, will be essential
to the translational success of imaging-genetics in ASD. Finally,
a promising and relatively novel approach is the combination
of transcranial magnetic stimulation with electroencephalogra-
phy or fMRI. This combination can provide new insights into
brain function, with high temporal resolution, and can measure
altered plasticity in neuropsychiatric disorders, which may be a
useful neural phenotype for geneticmapping (Pascual-Leone et al.,
2011).
Advancements in the widespread ability to acquire non-
invasive, high quality brain imaging scans, quickly, and during
natural sleep, has made it feasible to undertake neuroimaging of
infants at high genetic risk for ASD. Further, preliminary longitu-
dinal neuroimaging results have indicated that brain differences
in ASD may be detectable prior to the development of ASD symp-
toms (Wolff et al., 2012). These exciting ﬁndings suggest that early
neuroimaging biomarkers of risk patterns forASD expression may
be within reach. Using the imaging-genetics approach, infants at
high genetic risk for ASD may be further stratiﬁed according to
brain-based phenotypes associated with discrete genetic risk fac-
tors that signal vulnerability for developing ASD symptoms, based
on altered brain development. This stratiﬁcation could then cue
opportunities for customized therapeutic interventions that could
be implemented early, while the brain is highly plastic and the
full potential to normalize brain development and optimize out-
come may be realized. For such translational advancement to take
place, the availability of genetically based animal models will be
crucial to create opportunities to: (i) study the effects of speciﬁc
genes, or gene systems on brain development, in a controlled set-
ting, using high resolution imaging, and phenotyping to validate
brain–behavior relationships, and (ii) test novel therapeutics and
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their effects on brain development and behavior. A developmen-
tal approach to imaging-genetics research in ASD may move the
promise of this ﬁeld into the clinical domain and toward delivery
of targeted therapeutic options to affected individuals and their
families.
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